10 studies found for:    MEDI522
Show Display Options
Rank Status Study
1 Completed Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Metastatic Melanoma
Interventions: Biological: MEDI--522;   Biological: Integrin + Dacarbazine
2 Completed Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Biological: MEDI-522
3 Terminated
Has Results
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: etaracizumab;   Biological: bevacizumab
4 Completed Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Condition: Cancer
Intervention: Drug: MEDI-522
5 Completed Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Condition: Cancer
Intervention: Drug: MEDI-522
6 Completed Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Biological: MEDI-522;   Other: Placebo
7 Completed MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: MEDI-522;   Biological: Docetaxel + Prednisone* + Zoledronic Acid
8 Completed Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: MEDI-522;   Other: Placebo
9 Completed Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: etaracizumab
10 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Biological: etaracizumab

Indicates status has not been verified in more than two years